<DOC>
	<DOCNO>NCT02777931</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , parallel-group study NFC-1 versus placebo adolescent ADHD genetic disorder impact mGluRs .</brief_summary>
	<brief_title>Efficacy Safety NFC-1 Adolescents With Genetic Disorders Impacting mGluR ADHD</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , parallel-group study adolescent ADHD genetic disorder impact mGluRs . Approximately 90 subject receive randomize treatment NFC-1 placebo . Dosing optimize first 4 week treatment , base clinical response tolerability , maintain additional 2 week .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<criteria>Subject ADHD define Diagnostic Statistical Manual Mental Disorders , 5th edition ( DSM5 ) Version 5 Attention Deficit Hyperactivity Disorder Rating Scale ( ADHDRS5 ) â‰¥ 28 Baseline without conventional ADHD therapy . Subject intelligence quotient ( IQ ) &gt; 79 , base Wechsler Abbreviated Scale Intelligence , second edition ( WASIII ) . Subject genotyped previously determine disruptive mutation gene within glutamate receptor metabotropic ( GRM ) network determine presence copy number variation ( CNVs ) ( GRM biomarkerpositive subject ) . The confirmation subject 's positive status provide sponsor . Subject judge general good health , ADHD , base medical history , physical examination , vital sign measurement , laboratory safety test , Columbia Suicide Severity Rating Scale ( CSSRS ) perform Screening Visit and/or prior administration investigational product ( IP ) . Subject clinically significant abnormality electrocardiogram ( ECG ) perform Screening Visit and/or prior administration IP serious arrhythmia , bradycardia , tachycardia , cardiac conduction problem , abnormality deem potential safety issue . Parent/legal guardian subject understand study procedure agree subject 's participation study indicate parental/legal guardian signature subject inform consent form subject signature assent form . Subjects prior diagnosis comorbid major psychiatric disorder ( ie , aside ADHD ) , include major depression , bipolar disease , schizophrenia , pervasive development disorder , intellectual disability . Subject currently take prohibit medication and/or unwilling wean current ADHD medication participate study Subject history illness opinion study investigator might confound result study pose additional risk subject participation study . Subject known history presence syncope , cardiac conduction problem ( eg , clinically significant heart block ) , exerciserelated cardiac event include syncope presyncope , clinically significant bradycardia . Subject history stroke , chronic seizure , major neurological disorder , opinion investigator , would interfere subject 's ability participate and/or evaluate study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>